18.09.2015 12:00:00 CET

Nexstim Plc ("Nexstim" or the "Company") Nexstim Plc Certified Adviser Change

Helsinki, 18 September 2015 at 13:00 pm

Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to improve rehabilitation for stroke patients through the use of non-invasive brain stimulation, today announces that it has changed its Certified Advisor from UB Capital Ltd to UB Securities Ltd. The change is effective of 21st September 2015 and the Certified Adviser to Nexstim until 18th September 2015 was UB Capital Ltd.

Janne Huhtala, CEO

For further information please visit www.nexstim.com or contact:

Nexstim                                                                                                                                                              +358 +358 (0)40 8615046
Janne Huhtala, Chief Executive Officer                                                                              janne.huhtala@nexstim.com

UB Securities Ltd. (Certified Adviser)                                                                                                     +358 (0)9 2538 0254

Consilium Strategic Communications                                                                                                    +44 (0)20 3709 5700
Mary-Jane Elliott / Ivar Milligan                                                                                      nexstim@consilium-comms.com

About Nexstim Plc
Nexstim, formed in 2000 and based in Finland, is a medical technology company aiming to improve rehabilitation for stroke patients. Nexstim has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) device for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the company has developed a device for stroke therapy called Navigated Brain Therapy (NBTŪ). In H1 2014, Nexstim initiated a two-year pivotal Phase III study at 12 sites in the US aiming to demonstrate the effectiveness of NBTŪ and gain FDA clearance for commercialisation in post-acute stroke therapy in the US. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com.

Nexstim Plc.release